Gainers

• Artelo Biosciences (NASDAQ:ARTL) shares rose 433.9% to $17.03 during Friday's regular session. The company's market cap stands at $2.3 million.
• Polaryx Therapeutics (NASDAQ:PLYX) stock rose 30.56% to $8.33. The company's market cap stands at $302.0 million.
• Agape ATP (NASDAQ:ATPC) shares increased by 25.11% to $2.79. The company's market cap stands at $2.2 million.
• Universe Pharmaceuticals (NASDAQ:UPC) shares moved upwards by 22.22% to $2.86. The company's market cap stands at $1.3 million.
• MiNK Therapeutics (NASDAQ:INKT) stock rose 18.69% to $11.43. The company's market cap stands at $45.2 million.
• ADMA Biologics (NASDAQ:ADMA) shares increased by 14.23% to $9.47. The market value of their outstanding shares is at $1.9 billion.

Losers

• Iterum Therapeutics (NASDAQ:ITRM) stock fell 78.1% to $0.04 during Friday's regular session. The market value of their outstanding shares is at $9.2 million.
• XORTX Therapeutics (NASDAQ:XRTX) shares fell 77.98% to $0.38. The market value of their outstanding shares is at $2.4 million.
• Iridex (NASDAQ:IRIX) shares decreased by 27.59% to $0.98. The company's market cap stands at $23.2 million. As per the press release, Q4 earnings came out yesterday.
• Cognition Therapeutics (NASDAQ:CGTX) stock fell 26.85% to $0.79. The company's market cap stands at $96.5 million. The company's, Q4 earnings came out yesterday.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) stock fell 26.77% to $0.63. The company's market cap stands at $4.8 million.
• Alzamend Neuro (NASDAQ:ALZN) shares fell 23.34% to $1.15. The market value of their outstanding shares is at $5.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.